Home
/
Whitehawk Therapeutics, Inc.
/
Financials
/
Quarterly
Whitehawk Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Whitehawk Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 6, 2025
Q2
2025
Jun 30, 2025
$0
Aug 7, 2025
Q1
2025
Mar 31, 2025
$7.15M
May 8, 2025
Q3
2025
Sep 30, 2024
$7.21M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$6.18M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$5.35M
May 8, 2025
Q3
2024
Sep 30, 2023
$5.96M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$6.20M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$5.87M
May 8, 2024
Q3
2023
Sep 30, 2022
$4.25M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$3.44M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$2.31M
May 10, 2023
Q2
2022
Dec 31, 2021
$14.00M
Aug 10, 2022
Q3
2022
Sep 30, 2021
$0
Nov 9, 2022
Q2
2022
Jun 30, 2021
$0
Aug 10, 2022
Q1
2022
Mar 31, 2021
$120.0K
May 12, 2022
Q3
2023
Dec 31, 2020
$14.00M
Nov 8, 2023
Q1
2024
Dec 31, 2020
$14.00M
May 8, 2024
Q2
2024
Dec 31, 2020
$14.00M
Aug 7, 2024
Q3
2021
Sep 30, 2020
$231.0K
Nov 10, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($17.75M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
($52.62M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($52.62M)
Aug 7, 2025
Q3
2025
Mar 31, 2025
$73.02M
Nov 6, 2025
Q1
2025
Mar 31, 2025
$73.02M
May 8, 2025
Q2
2025
Mar 31, 2025
$73.02M
Aug 7, 2025
Q3
2025
Sep 30, 2024
($12.55M)
Nov 6, 2025
Q3
2025
Jun 30, 2024
($14.58M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($14.58M)
Aug 7, 2025
Q2
2025
Mar 31, 2024
($18.29M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($18.29M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($18.29M)
May 8, 2025
Q3
2024
Sep 30, 2023
($16.30M)
Nov 6, 2024
Q3
2024
Jun 30, 2023
($17.97M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($17.97M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($15.22M)
May 8, 2024
Q2
2024
Mar 31, 2023
($15.22M)
Aug 7, 2024
Q3
2024
Mar 31, 2023
($15.22M)
Nov 6, 2024
Q3
2023
Sep 30, 2022
($14.47M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($18.27M)
Aug 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($19.55M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($54.75M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($15.22M)
May 8, 2025
Q3
2025
Sep 30, 2024
($13.41M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($15.58M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($19.51M)
May 8, 2025
Q3
2024
Sep 30, 2023
($17.85M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($19.55M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($16.83M)
May 8, 2024
Q3
2023
Sep 30, 2022
($15.04M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($18.36M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($13.81M)
May 10, 2023
Q3
2022
Sep 30, 2021
($87.31M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($3.88M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
($4.09M)
May 12, 2022
Q3
2021
Sep 30, 2020
($2.66M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
$9.26M
Aug 11, 2021
Q1
2021
Mar 31, 2020
($4.11M)
May 17, 2021
Q3
2020
Sep 30, 2019
($4.97M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($5.98M)
Aug 12, 2020